Newsletter Tool

To view this email as a web page, click here

Today's Rundown

J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDA
A $200M injection from the U.S. will allow Aspen to produce more Johnson & Johnson COVID-19 vaccines for Africa
More medical provider groups push healthcare employers to require COVID-19 vaccination
Abbott returns to pre-pandemic growth, clocking 11% sales bump from 2019 sans COVID testing revenues
COVID-19 tracker: EMA warns of a possible link between Johnson & Johnson vax and neurological disorder; EU lagging on vaccine donation pledge
Quest Diagnostics sees ‘faster than expected’ return in base testing business as routine healthcare rebounds
IQVIA, BREATHE team up for early diagnosis, treatment of respiratory conditions

Featured Story

J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDA

By Noah Higgins-Dunn

Johnson & Johnson’s COVID-19 vaccine presents greater benefits than it does safety risks, especially amid the quickly spreading Delta variant, a key CDC expert panel decided. However, the panel said that a ruling over the need for a booster added to all COVID shots will have to start with the FDA.

A $200M injection from the U.S. will allow Aspen to produce more Johnson & Johnson COVID-19 vaccines for Africa

By Kevin Dunleavy

With a $200 million grant from the U.S., Aspen Pharmacare of South Africa will increase its capacity to produce the Johnson & Johnson COVID-19 vaccine. Only 1.5% of the continent's 1.3 billion people have been fully vaccinated.

More medical provider groups push healthcare employers to require COVID-19 vaccination

By Dave Muoio

AHA, AEH and AAMC join other professional groups backing mandatory COVID-19 vaccination policies as nationwide hospitalization rates tick upward. No small number of hospitals and health systems have already chosen to implement the requirements for a collective hundreds of thousands of healthcare staff.

Abbott returns to pre-pandemic growth, clocking 11% sales bump from 2019 sans COVID testing revenues

By Andrea Park

After more than a year spent devoting much of its attention to developing COVID tests, Abbott saw double-digit sales growth across its entire business in the second quarter of 2021, even without the inclusion of COVID-related earnings.

COVID-19 tracker: EMA warns of a possible link between Johnson & Johnson vax and neurological disorder; EU lagging on vaccine donation pledge

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Europe's drug regulator has warned of a possible link between the Johnson & Johnson vaccine and the rare neurological disorder Guillain-Barre syndrome. Europe is lagging behind on its pledge to deliver 160 million COVID-19 vaccine doses to poorer nations. And more headlines.

Quest Diagnostics sees ‘faster than expected’ return in base testing business as routine healthcare rebounds

By Conor Hale

Though demand for COVID-19 testing this year has receded faster than many diagnostics companies expected, the quick return of patients to the clinic for routine care—such as screenings for heart disease or cancer—may be picking up the slack.

IQVIA, BREATHE team up for early diagnosis, treatment of respiratory conditions

By Kyle LaHucik

Clinical research services provider IQVIA is partnering with respiratory health research hub BREATHE to use health data for early diagnosis of respiratory conditions, accelerate potential personalized treatments, potentially open pathways for long COVID treatment and also attract more Big Pharma and biotech investment in the UK.

COVID-19 Tracker